Evidence map›Paper›PMID 30188599›Full record

ArticleJournal of cellular and molecular medicine2018

Hiding in Plain Sight: Nebivolol Exhibits Compelling Tocolytic Properties.

Scott D Barnett, Iain L O Buxton

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Novel Tocolytic Strategy: Modulating Cx43 Activity byThe Journal of pharmacology and experimental therapeutics · 2021
    Article
  3. Hiding in Plain Sight: Nebivolol Exhibits Compelling Tocolytic Properties.Journal of cellular and molecular medicine · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Scott D BarnettPharmacology, University of Nevada, Reno School of Medicine, Reno, Nevada.ORCID 0000-0002-2269-2525
Iain L O BuxtonPharmacology, University of Nevada, Reno School of Medicine, Reno, Nevada.ORCID 0000-0002-2775-6137
University of Nevada, Reno · US

Funding

Tracking and EvaluationU54GM104944 · NIGMS · UNIVERSITY OF NEVADA LAS VEGAS · PI KUMAR, PARVESH · 2013 to 2023
$39.6M
Regulation of CAP Protein S-Nitrosation in Preterm LaborR01HD091114 · NICHD · UNIVERSITY OF NEVADA RENO · PI BUXTON, IAIN L · 2018 to 2021
$2.0M
REGULATION OF MYOMETRIAL RELAXATION: AGONIST-SPECIFIC cGMP ACTIONR01HD053028 · NICHD · UNIVERSITY OF NEVADA RENO · PI BUXTON, IAIN L · 2007 to 2011
$1.4M
Eunice Kennedy Shriver National Institute of Child Health and Human Development HD053028NICHD NIH HHS R01 HD091114NIGMS NIH HHS U54GM 104944
6 · The paper itself

Abstract

Preterm birth before 37 weeks of completed gestation results in numerous health consequences for the foetus. Preterm labour leads to preterm birth in over 50% of cases, and no FDA-approved treatment can prevent labour or help a foetus remain in the womb until term. Examination of nitric oxide mediated relaxation signaling in the uterine smooth muscle reveals a role for protein S-nitrosation. The recent discovery of upregulated S-nitrosoglutathione reductase (GSNOR) in spontaneously preterm labouring women has emphasized the need to explore the function of S-nitrosation regulation in the maintenance of uterine quiescence. Here we have examined the ability of nebivolol to relax uterine smooth muscle and tested recent claims that nebivolol is a GSNOR inhibitor. In uterine smooth muscle strips from both mouse and human, nebivolol relaxes oxytocin-induced contractions in a dose dependent manner. Our data indicates that nebivolol has no effect on GSNOR activity, nor does nebivolol inhibit thioredoxin reductase, two of the major protein denitrosylases. The ability of nebivolol to relax uterine smooth muscle is likely the combined effects of increased nitric oxide synthase activity and β3-adregnegic stimulation.

Indexed as

Aldehyde OxidoreductasesAnimalsFemaleHumansLabor, ObstetricMiceMuscle, SmoothMyometriumNebivololNitric OxideNitrosationObstetric Labor, PrematureOxidation-ReductionPregnancyPremature BirthSignal TransductionAldehyde Oxidoreductasesformaldehyde dehydrogenase, glutathione-independentNebivololNitric OxideTocolytic AgentsADH5 nebivololGSNOGSNOR GSNO reductasenitric oxidepregnancypreterm laboursmooth muscleS-Nitrosoglutathione

Identifiers

PMID30188599
PMCPMC6237580
OpenAlexW2890939984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.